Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment (NCT01548573) | Clinical Trial Compass
TerminatedPhase 2
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
Stopped: Met study stopping rules
United States19 participantsStarted 2012-05
Plain-language summary
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding bortezomib (Velcade®), thalidomide, gemcitabine and carmustine to the transplant regimens to down-regulate the rescue of myeloma cells by the micro-environment and to prevent DNA repair post high-dose alkylating agent therapy. By reducing drug resistance, it is hoped that 3-year event-free survival will be increased significantly when compared to Total Therapy II. Additionally, participants will have the option of providing biospecimens for a sub-study evaluating gene expression profiling at specific timepoints to better understand drug-resistance in myeloma, and to determine whether there are genes or gene products in the resistant population that can be targeted by novel therapies.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participants must have had a diagnosis of symptomatic MM, MM + amyloidosis, or POEMS (osteosclerotic myeloma: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) requiring treatment. Participants with a previous history of smoldering myeloma will be eligible if there is evidence of progressive disease requiring chemotherapy. Note that study participants do not need to have active disease at the time of study entry, as participants may have received up to 12 months of prior chemotherapy, which might have induced a response.
✓. Protein criteria must be present (quantifiable M-component of IgG, IgA, IgD, or IgE and/or urinary kappa or lambda light chain, Bence-Jones protein, or Free Kappa Light Chain or Free Lambda Light Chain) in order to evaluate response. Non-secretory participants are eligible provided the participant has \> 20% plasmacytosis OR multiple (\>3) focal plasmacytomas or focal lesions on MRI.
✓. Participants must have received no more than 12 months of prior chemotherapy for this disease. Participants may have received prior radiotherapy provided approval has been obtained from the PI.
✓. Participants must not have had a prior transplant.
✓. Participants must be 18-80 years of age at the time of study entry.
✓. Ejection fraction by ECHO or MUGA of ≥ 40% performed.
✓. Participants must have adequate pulmonary function studies, \> 50% of predicted on mechanical aspects (FEV1, FVC) and diffusion capacity (DLCO) \> 50% of predicted (adjusted for hemoglobin). If the participant is unable to complete pulmonary function tests due to disease related pain or condition, a participant may still be enrolled provided that the PI or enrolling investigator documents that the participant is a transplant candidate.
✓. Participants must have a creatinine \< 3 mg/dl and a calculated creatinine clearance \>30mL/min. The Cockroft-Gault equation may be used to obtain calculated creatinine clearance.
Exclusion criteria
✕. Prior autologous or allogeneic transplant.
✕. Platelet count \< 30 x 109/L, unless myeloma-related. If MM-related, the enrolling investigator must document this.
✕. \> grade 3 neuropathy.
✕. Known hypersensitivity to bortezomib, boron, or mannitol.
✕. Uncontrolled diabetes.
✕. Recent (\< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias.
✕. Participants must not have light chain deposition disease-related renal failure or creatinine \>3 mg/dl.
✕. Participants must not have a concurrent malignancy unless it can be adequately treated by surgical, non-chemotherapeutic intervention. Participants may have a history of prior malignancy, provided that he/she has not had any treatment within 365 days of study entry AND that life expectancy exceeds 5 years at the time of study entry.